Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Kazunori Aoki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1292-3764; OpenAlex author ID A5070444406. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 8

  1. MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218348↗
  2. Corrigendum to "MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinoma" [Cancer Lett. 645, (2026), 21834… Last author DOI 10.1016/j.canlet.2026.218794↗
  3. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Co-author DOI 10.1111/cas.15929↗
  4. Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine. Co-author DOI 10.7150/thno.25308↗
  5. A Tumor-targeting Adenovirus with High Gene-transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells. Last author DOI 10.21873/anticanres.11730↗
  6. A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues. Last author DOI 10.1016/j.jconrel.2014.07.053↗
  7. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Last author DOI 10.1111/cas.12332↗
  8. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. Co-author DOI 10.1111/cas.12196↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroyuki Tsunoda · 3 shared papers, 2023–2026 · strength 0.55
  2. Atsushi Ochiai · 3 shared papers, 2023–2026 · strength 0.55
  3. Nobuyoshi Hiraoka · 4 shared papers, 2014–2026 · strength 0.51
  4. Keisuke Sekine · 2 shared papers, 2026 · strength 0.40
  5. Satoshi Nara · 2 shared papers, 2026 · strength 0.40
  6. Hironori Fukuda · 2 shared papers, 2026 · strength 0.40
  7. Minoru Esaki · 2 shared papers, 2026 · strength 0.40
  8. Mami Takahashi · 1 shared paper, 2026 · strength 0.20
  9. Yuki Yamamoto · 3 shared papers, 2014–2017 · strength 0.15
  10. Shuichi Mitsunaga · 1 shared paper, 2023 · strength 0.15
  11. Kazuo Watanabe · 1 shared paper, 2023 · strength 0.15
  12. Mitsuhito Sasaki · 1 shared paper, 2023 · strength 0.15
  13. Masafumi Ikeda · 1 shared paper, 2023 · strength 0.15
  14. Toshihiro Yamaguchi · 1 shared paper, 2023 · strength 0.15
  15. Hiroshi Imaoka · 1 shared paper, 2023 · strength 0.15
  16. Manendra Babu Lankadasari · 1 shared paper, 2018 · strength 0.09
  17. Kuzhuvelil B. Harikumar · 1 shared paper, 2018 · strength 0.09
  18. Masaki Nagasato · 1 shared paper, 2017 · strength 0.07
  19. Kouichirou Aida · 1 shared paper, 2014 · strength 0.04
  20. Teruhiko Yoshida · 1 shared paper, 2014 · strength 0.04
  21. Jun Kimura · 1 shared paper, 2013 · strength 0.03
  22. Masato Yamamoto · 1 shared paper, 2013 · strength 0.03
  23. Itaru Endo · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.